Spots Global Cancer Trial Database for inflammatory breast cancer
Every month we try and update this database with for inflammatory breast cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early | NCT00957125 | Breast Cancer | Epirubicin Docetaxel Bevacizumab | 18 Years - | Karolinska University Hospital | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer | NCT00005822 | Breast Cancer | doxorubicin hyd... semaxanib conventional su... radiation thera... tamoxifen | 18 Years - | Case Comprehensive Cancer Center | |
| Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer | NCT00346229 | Breast Cancer | filgrastim pegfilgrastim lyso-thermosens... hyperthermia tr... | 18 Years - | Duke University | |
| Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer | NCT00450892 | Breast Cancer | docetaxel+lapat... docetaxel + tra... docetaxel + tra... | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Combination Chemotherapy in Treating Women With Breast Cancer | NCT00003679 | Breast Cancer | cyclophosphamid... docetaxel doxorubicin hyd... tamoxifen citra... conventional su... radiation thera... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer | NCT01938833 | HER2-negative B... Inflammatory Br... Male Breast Can... Recurrent Breas... Stage IV Breast... | Romidepsin Abraxane | 18 Years - | Thomas Jefferson University | |
| A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer | NCT05415215 | Early Breast Ca... Locally Advance... Inflammatory Br... | Fixed Dose Comb... Pertuzumab IV Trastuzumab IV Trastuzumab Emt... Investigator's ... Surgery Radiotherapy | 18 Years - | Hoffmann-La Roche | |
| Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer | NCT00066443 | Breast Cancer | pegfilgrastim docetaxel epirubicin hydr... | 16 Years - | Canadian Cancer Trials Group | |
| Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | NCT00398489 | Breast Cancer | trastuzumab anastrozole cyclophosphamid... docetaxel epirubicin hydr... goserelin aceta... tamoxifen citra... adjuvant therap... conventional su... neoadjuvant the... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer | NCT00856492 | Breast Cancer | bevacizumab pegfilgrastim cyclophosphamid... doxorubicin hyd... paclitaxel albu... | 18 Years - | SWOG Cancer Research Network | |
| Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer | NCT00096343 | Breast Cancer | carboplatin paclitaxel | 18 Years - 120 Years | University of Alabama at Birmingham | |
| Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia | NCT00344071 | Inflammatory Br... | - | National Institutes of Health Clinical Center (CC) | ||
| Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients | NCT00820547 | Breast Cancer | bevacizumab cyclophosphamid... docetaxel epirubicin hydr... fluorouracil | 18 Years - | UNICANCER | |
| EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma | NCT00004261 | Breast Cancer Cervical Cancer Head and Neck C... Prostate Cancer Sarcoma | EF5 flow cytometry fluorescent ant... immunohistochem... biopsy | 18 Years - 120 Years | University Health Network, Toronto | |
| S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer | NCT00856492 | Breast Cancer | bevacizumab pegfilgrastim cyclophosphamid... doxorubicin hyd... paclitaxel albu... | 18 Years - | SWOG Cancer Research Network | |
| Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) | NCT01583426 | Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... Tubular Breast ... HER-2 Positive ... Inflammatory Br... Inflammatory Br... | nab-Paclitaxel Paclitaxel | 18 Years - | German Breast Group | |
| Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer | NCT02199418 | Tubular Breast ... Mucinous Breast... Invasive Ductal... Inflammatory Br... | Paclitaxel Cisplatin | 18 Years - 70 Years | RenJi Hospital | |
| Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer | NCT00003680 | Breast Cancer | CMF regimen cyclophosphamid... fluorouracil methotrexate tamoxifen citra... thiotepa peripheral bloo... radiation thera... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer | NCT00295893 | Breast Cancer | cyclophosphamid... docetaxel doxorubicin hyd... Trastuzumab Carboplatin Paclitaxel | 18 Years - 120 Years | City of Hope Medical Center | |
| Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer | NCT00016276 | Cardiac Toxicit... Inflammatory Br... Stage IIIA Brea... Stage IIIB Brea... Stage IV Breast... | dexrazoxane hyd... doxorubicin hyd... cyclophosphamid... paclitaxel trastuzumab therapeutic con... radiation thera... tamoxifen citra... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Docetaxel Followed by Surgery in Treating Women With Stage II or Stage III Breast Cancer | NCT00343512 | Breast Cancer | docetaxel protein express... laboratory biom... biopsy conventional su... neoadjuvant the... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) | NCT02125344 | Tubular Breast ... Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... HER2 Positive B... Inflammatory Br... | non-pegylated l... Carboplatin Paclitaxel Epirubicin Cyclophosphamid... Pertuzumab Trastuzumab Ferric carboxym... | 18 Years - | German Breast Group | |
| Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery | NCT00033397 | Breast Cancer | biopsy magnetic resona... radiomammograph... ultrasound imag... gadopentetate d... chemotherapy | 18 Years - | Alliance for Clinical Trials in Oncology | |
| NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer | NCT00499122 | Breast Cancer | Cyclophosphamid... Docetaxel Doxorubicin NOV 002 | 18 Years - 120 Years | University of Miami | |
| Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer | NCT01426880 | Tubular Breast ... Mucinous Breast... Breast Cancer F... Invasive Ductal... Tubular Breast ... HER-2 Positive ... Inflammatory Br... Inflammatory Br... | Carboplatin background trea... | 18 Years - | German Breast Group | |
| Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer | NCT03598257 | Breast Inflamma... | Biospecimen Col... Olaparib Radiation Thera... Survey Administ... | 18 Years - | National Cancer Institute (NCI) | |
| Refining Local-Regional Therapy for IBC | NCT04636710 | Breast Cancer Inflammatory Br... Sentinel Lymph ... | Lymphoscintigra... | 18 Years - | Dana-Farber Cancer Institute | |
| FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients. | NCT04200768 | Breast Neoplasm... | Prospective dat... | 18 Years - 75 Years | Universitaire Ziekenhuizen KU Leuven | |
| Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | NCT00513695 | Inflammatory Br... Male Breast Can... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | sunitinib malat... paclitaxel doxorubicin hyd... cyclophosphamid... filgrastim therapeutic con... laboratory biom... flow cytometry | - | University of Washington | |
| Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer | NCT04030507 | Breast Cancer HER2-positive B... Triple Negative... Hormone Recepto... Inflammatory Br... Metastatic Brea... | MRI | 18 Years - | Dana-Farber Cancer Institute | |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer | NCT03515798 | Inflammatory Br... | Pembrolizumab I... neoadjuvant EC-... | 18 Years - | Institut Paoli-Calmettes | |
| Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer | NCT00005798 | Breast Cancer | Carboplatin Cyclophosphamid... Thiotepa | 15 Years - 64 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early | NCT00957125 | Breast Cancer | Epirubicin Docetaxel Bevacizumab | 18 Years - | Karolinska University Hospital | |
| Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy | NCT00028704 | Breast Cancer | conventional su... radiation thera... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer | NCT00005842 | Cancer | trastuzumab tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer | NCT00118053 | Breast Cancer | herceptin carboplatin docetaxel conventional su... radiation thera... | 18 Years - | Rutgers, The State University of New Jersey | |
| Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer | NCT00464646 | Breast Cancer | Epirubicin Cyclophosphamid... Docetaxel Trastuzumab Bevacizumab | 18 Years - | NSABP Foundation Inc | |
| Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer | NCT00346229 | Breast Cancer | filgrastim pegfilgrastim lyso-thermosens... hyperthermia tr... | 18 Years - | Duke University | |
| Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) in Treating Women Undergoing Surgery for Stage II or Stage III Breast Cancer | NCT00397761 | Breast Cancer | capecitabine paclitaxel albu... neoadjuvant the... | 18 Years - 120 Years | Medstar Health Research Institute | |
| Dose-escalation Study of Oral CX-4945 | NCT00891280 | Advanced Solid ... Breast Cancer Inflammatory Br... Castleman's Dis... Multiple Myelom... | CX-4945 oral fo... | 18 Years - | Cylene Pharmaceuticals | |
| Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy | NCT00028704 | Breast Cancer | conventional su... radiation thera... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer | NCT00499122 | Breast Cancer | Cyclophosphamid... Docetaxel Doxorubicin NOV 002 | 18 Years - 120 Years | University of Miami | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer | NCT02623972 | Inflammatory Br... Human Epidermal... | Eribulin Adriamycin Cyclophosphamid... | 18 Years - | Dana-Farber Cancer Institute | |
| Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer | NCT00193206 | Breast Cancer | Gemcitabine Epirubicin Albumin-bound P... | 18 Years - | SCRI Development Innovations, LLC | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Trastuzumab and External Beam Radiation Therapy in Treating Women With Stage III or Stage IV Breast Cancer | NCT00943410 | Breast Cancer | external beam r... Herceptin | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Doxorubicin and Docetaxel in Treating Women With Stage III Breast Cancer | NCT00005800 | Breast Cancer | Filgrastim Docetaxel Doxorubicin Surgery | 18 Years - 70 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| S0012 Doxorubicin, Cyclophosphamide, and Paclitaxel With or Without Filgrastim in Treating Women With Inflammatory or Locally Advanced Breast Cancer | NCT00016406 | Breast Cancer | filgrastim cyclophosphamid... doxorubicin paclitaxel surgery | 18 Years - | SWOG Cancer Research Network | |
| Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer | NCT01880385 | Inflammatory Br... | Bevacizumab Cyclophosphamid... epirubicin hydr... fluorouracil Docetaxel Trastuzumab | 20 Years - 75 Years | Association Tunisienne de lutte Contre le Cancer | |
| Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | NCT02879513 | Invasive Ductal... Tubular Breast ... Mucinous Breast... Inflammatory Br... | Paclitaxel Cisplatin Epirubicin Cyclophosphamid... 5-fluoruracil | 18 Years - 70 Years | RenJi Hospital | |
| Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | NCT00398489 | Breast Cancer | trastuzumab anastrozole cyclophosphamid... docetaxel epirubicin hydr... goserelin aceta... tamoxifen citra... adjuvant therap... conventional su... neoadjuvant the... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients. | NCT04200768 | Breast Neoplasm... | Prospective dat... | 18 Years - 75 Years | Universitaire Ziekenhuizen KU Leuven | |
| Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer | NCT00193206 | Breast Cancer | Gemcitabine Epirubicin Albumin-bound P... | 18 Years - | SCRI Development Innovations, LLC | |
| Breast-Conserving Therapy Compared With Mastectomy Followed By Radiation Therapy in Treating Women With Locally Advanced Breast Cancer Previously Treated With Chemotherapy | NCT00028704 | Breast Cancer | conventional su... radiation thera... | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer | NCT00096343 | Breast Cancer | carboplatin paclitaxel | 18 Years - 120 Years | University of Alabama at Birmingham | |
| AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer | NCT00310089 | Breast Cancer | filgrastim pegfilgrastim cediranib malea... cyclophosphamid... docetaxel doxorubicin hyd... laboratory biom... conventional su... neoadjuvant the... | 18 Years - | National Cancer Institute (NCI) | |
| Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer | NCT00002627 | Breast Cancer | filgrastim carboplatin cyclophosphamid... mesna paclitaxel peripheral bloo... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Phase II Neoadjuvant in Inflammatory Breast Cancer | NCT00756470 | Breast Cancer | Lapatinib Paclitaxel 5-Fluorouracil ... Epirubicin Cyclophosphamid... | 18 Years - | M.D. Anderson Cancer Center | |
| Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery | NCT00033397 | Breast Cancer | biopsy magnetic resona... radiomammograph... ultrasound imag... gadopentetate d... chemotherapy | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Enhanced Ultrasound in Determining Extent of Disease in Women With Primary Breast Cancer | NCT00005058 | Breast Cancer | ultrasound imag... | 18 Years - | National Cancer Institute (NCI) | |
| Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer | NCT00004925 | Breast Cancer | trastuzumab pegylated lipos... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer | NCT00513695 | Inflammatory Br... Male Breast Can... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | sunitinib malat... paclitaxel doxorubicin hyd... cyclophosphamid... filgrastim therapeutic con... laboratory biom... flow cytometry | - | University of Washington | |
| FATLAS: Comprehensive Multi-level Characterization of Systemic and Mammary Adiposity in Breast Cancer Patients. | NCT04200768 | Breast Neoplasm... | Prospective dat... | 18 Years - 75 Years | Universitaire Ziekenhuizen KU Leuven | |
| EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma | NCT00004261 | Breast Cancer Cervical Cancer Head and Neck C... Prostate Cancer Sarcoma | EF5 flow cytometry fluorescent ant... immunohistochem... biopsy | 18 Years - 120 Years | University Health Network, Toronto | |
| Exercise Program or Health Education Program in Reducing Fatigue and Pain in Breast Cancer Survivors | NCT00336089 | Breast Cancer Cancer Survivor Fatigue Pain | exercise interv... educational int... complementary o... fatigue assessm... management of t... pain therapy quality-of-life... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| Exercise Program or Health Education Program in Reducing Fatigue and Pain in Breast Cancer Survivors | NCT00336089 | Breast Cancer Cancer Survivor Fatigue Pain | exercise interv... educational int... complementary o... fatigue assessm... management of t... pain therapy quality-of-life... | 18 Years - 60 Years | National Cancer Institute (NCI) | |
| NOV-002, Doxorubicin, Cyclophosphamide, and Docetaxel in Women With Newly Diagnosed Stage II or IIIC Breast Cancer | NCT00499122 | Breast Cancer | Cyclophosphamid... Docetaxel Doxorubicin NOV 002 | 18 Years - 120 Years | University of Miami | |
| SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer | NCT00005822 | Breast Cancer | doxorubicin hyd... semaxanib conventional su... radiation thera... tamoxifen | 18 Years - | Case Comprehensive Cancer Center | |
| Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy | NCT02879513 | Invasive Ductal... Tubular Breast ... Mucinous Breast... Inflammatory Br... | Paclitaxel Cisplatin Epirubicin Cyclophosphamid... 5-fluoruracil | 18 Years - 70 Years | RenJi Hospital | |
| MUC1 Vaccine for Triple-negative Breast Cancer | NCT00986609 | Breast Cancer Inflammatory Br... Stage I Breast ... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-negative... | MUC-1 peptide v... poly ICLC MUC1 peptide-po... laboratory biom... enzyme-linked i... flow cytometry | 18 Years - | Case Comprehensive Cancer Center | |
| Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer | NCT00450892 | Breast Cancer | docetaxel+lapat... docetaxel + tra... docetaxel + tra... | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer | NCT00003199 | Estrogen Recept... Estrogen Recept... Inflammatory Br... Male Breast Can... Progesterone Re... Progesterone Re... Stage IIIB Brea... Stage IV Breast... | tamoxifen citra... busulfan thiotepa melphalan aldesleukin sargramostim peripheral bloo... radiation thera... | 19 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer | NCT03598257 | Breast Inflamma... | Biospecimen Col... Olaparib Radiation Thera... Survey Administ... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Before Surgery in Treating Women With Breast Cancer | NCT00008034 | Breast Cancer | capecitabine cyclophosphamid... epirubicin hydr... | 18 Years - 70 Years | European Organisation for Research and Treatment of Cancer - EORTC | |
| AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer | NCT00310089 | Breast Cancer | filgrastim pegfilgrastim cediranib malea... cyclophosphamid... docetaxel doxorubicin hyd... laboratory biom... conventional su... neoadjuvant the... | 18 Years - | National Cancer Institute (NCI) | |
| Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer | NCT02324088 | Inflammatory Br... | Docetaxel Cyclophosphamid... Epirubicin | 18 Years - 60 Years | UNICANCER | |
| Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy | NCT06131632 | Inflammatory Br... | Breast conservi... Radical modifie... | 18 Years - 70 Years | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
